This prescribing review protocol is based on the recommendations for the management of migraine made in SIGN Guideline 107 and the NHS D&G Joint Formulary. It covers the use of opiates in migrane, triptan overuse and formulary compliance.
Mesalazine is an aminosalicylate that is used routinely to induce and maintain remission in chronic inflammatory bowel disease – ulcerative colitis and Crohn’s disease.
This audit protocol supports the review of patients who are taking Dipyridamole MR for the secondary prevention of occlusive events following ischaemic stroke, TIA or amaurosis fugax.